SAVE Moms and Babies Act of 2026

Enhanced Practitioner Certification and Capabilities: Under Section 2(a)(2)(C)(ii), practitioners must be certified and demonstrate specific abilities, such as assessing pregnancy duration, diagnosing ectopic pregnancies, and providing surgical intervention for complications. This ensures those prescribing the drugs have specific medical skills.

Increased Safety and Access to Emergency Care: Section 2(a)(2)(C)(ii)(I) requires practitioners to ensure patients have access to medical facilities equipped for blood transfusions and resuscitation, which may provide a safety net for severe complications.

Strict Monitoring of Adverse Events: Section 2(a)(2)(C)(ii)(V) and Section 2(a)(3) require the reporting of deaths, hospitalizations, infections, or other adverse events to the FDA and manufacturers, which could help track the safety of these drugs.

Prohibition of Certain Investigational Uses: Section 2(a)(1)(B) prohibits investigational use exemptions for any investigation where the unborn child of a known pregnant woman is knowingly destroyed.

Restrictions on Drug Access: Section 2(a)(2)(A)(ii) prohibits the dispensing of previously approved abortion drugs by any means other than in-person administration by a prescribing health care practitioner, and Section 2(a)(2)(C)(iii) limits dispensing strictly to clinics, medical offices, or hospitals.

Prohibition of New Drug Approvals: Section 2(a)(1)(A) prevents the Secretary from approving any new applications for the marketing of abortion drugs.

Limitations on Use Duration: Section 2(a)(2)(A)(i) prevents any labeling changes that would approve the use of such drugs after 70 days gestation.

Rescinding of Investigational Exemptions: Section 2(b) dictates that existing investigational use exemptions will be deemed rescinded three years after the act's enactment if they would otherwise be prohibited under the new rules.